The Phase III POTENT trial (jRCTs051180057/CRB5180002) investigated the efficacy of S-1 with adjuvant endocrine therapy in patients with stage I to IIIB ER-positive, HER2-negative early breast cancer [15]. This evidence concerns the gene ESR1 and breast cancer.